Children as young as 8 years old should be screened for anxiety and those ages 12 and over for depression, according to new recommendations by the government-backed U.S. Preventive Services Task Force (USPSTF).
Many countries around the world that appeared to have kicked COVID-19 are reporting surges, largely the result of the so-called “stealth” Omicron variant, BA.2.
AbbVie bolstered the company’s neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion.
Sage Therapeutics Inc.’s drug helped improve depressive symptoms after three days in a late-stage study, but investor concerns over how long the treatment’s effect would last sent the drug developer’s shares down 17% on February 16.
Almost one year after Biogen forged a collaboration with Sage Therapeutics worth $1.52 billion, the development deal for the experimental major depressive disorder treatment zuranolone is bearing fruit that will support an expected rolling New Drug Application during 2022.
COMPASS Pathways revealed positive topline results from the mental healthcare firm’s Phase IIB clinical trial on the use of COMP360 psilocybin to address treatment-resistant depression (TRD).
A new study helps quantify the improved protection against Covid-19 achieved with a third booster dose of the vaccine from Pfizer Inc. and BioNTech SE in cancer patients who are undergoing chemotherapy.
Sage Therapeutics and Biogen announced positive and consistent results from their ongoing clinical trials on the efficacy and safety of zuranolone in treating major depressive disorder (MDD) and postpartum depression (PPD).
Sage Therapeutics ended two late-stage studies of the depression drug zuranolone after discussions with the U.S. Food and Drug Administration led the company to believe they were unnecessary for potential regulatory approval.
Sage Therapeutics’ experimental depression drug showed significant improvement in symptoms compared to placebo in a late-stage study.